AZURE BIOSYSTEMS INC.

Azure Biosystems, Inc. , based in the US, specializes in developing advanced life science instruments and reagents, particularly in biomolecular imaging and PCR systems, aimed at enhancing scientific research. Founded in 2013 in Dublin, US, Azure Biosystems, Inc. focuses on high-quality life science tools and imaging systems.

The company has remained dedicated to its core offerings without notable pivots. In November 2025, BroadOak Capital Partners invested in Azure Biosystems, Inc. Financial terms of the transaction were not disclosed. Azure Biosystems specializes in high-quality life science instruments and reagents, focusing primarily on biomolecular imaging and real-time PCR systems.

Their flagship product, the Sapphire FL Biomolecular Imager, is notable for its high-resolution imaging capabilities, customizable optical modules, and versatility in accommodating various research applications, including Western blotting, tissue imaging, and in vivo studies. The company also offers a range of reagents and consumables tailored to enhance workflows in protein analysis, genomics, and molecular biology, catering to a diverse client base that encompasses academic research institutions, clinical laboratories, and biotechnology firms across North America, Europe, and Asia. These products are designed to facilitate efficient data acquisition and analysis, enabling researchers to produce reliable results that drive scientific discovery. Azure Biosystems engages primarily in B2B transactions, providing specialized imaging systems and reagents directly to research laboratories and institutions.

The revenue model typically revolves around the sale of instruments such as the Sapphire FL and associated consumables, alongside potential service agreements for maintenance and support. The sales structure includes direct sales to end-users and partnerships with distributors catering to specific geographical markets. Azure's pricing strategy reflects the advanced technology and high-quality standards of its products. By offering comprehensive solutions that integrate both hardware and reagents, Azure positions itself as a key player in the life sciences sector, supporting applications from basic research to clinical diagnosis.

In November 2025, BroadOak Capital Partners invested in Azure Biosystems, Inc. to expand the company's platform reach and enhance its products for life sciences organizations. This investment aligns with plans to develop and launch new products, although specific product launch dates have not been disclosed. Azure Biosystems aims to expand into new markets, targeting regions across North America, Europe, and Asia by the end of 2025.